This study is a multicenter, open-label, postmarketing surveillance study. The substudy will collect information on BMD in adolescents and young adults with GHD or Turner syndrome who are completing growth hormone (GH) treatment for statural indications.

Condition	Phase
Dwarfism, Pituitary Turner Syndrome	Phase IV

Further Study Details: 

Ages Eligible for Study:  up to  17 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Bone age of at least 15 years for girls or at least 16 years for boys within 6 months of obtaining the DXA scan
• Previous enrollment in the NCGS core study, 85-036
• Tanner Stage 4 or greater
• Either spontaneous or induced puberty
• Subjects who plan on terminating GH treatment for statural purposes for one or more of the following reasons: epiphyseal fusion, slowing growth rate indicates that near adult height has been reached, or satisfied with current height

Exclusion Criteria:

• Current therapy with a non Genentech GH product
• Pregnancy (to avoid exposure to low levels of radiation from DXA scanners)
• Bilateral hip replacement
• Weight >130 kg (286 lb.)

California
      Genentech Central Contact, South San Francisco,  California,  94080,  United States; Recruiting

Study ID Numbers:  85-036, Substudy 10
Record last reviewed:  March 2005
Last Updated:  March 3, 2005
Record first received:  November 24, 2004
ClinicalTrials.gov Identifier:  NCT00097526
Health Authority: United States: Institutional Review Board (Awaiting confirmation)
ClinicalTrials.gov processed this record on 2005-04-08